PasiAnteroJanneMDMD, PhD

Oncology • Boston, MA

Associate Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Janne is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Janne's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-6036

Fax+1 617-582-7683
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
Brigham and Women's HospitalInternship, Internal Medicine, 1996 - 1997
Perelman School of Medicine at the University of PennsylvaniaClass of 1996

Certifications & Licensure

MA State Medical License 1998 - 2024
RI State Medical License 2020 - 2020

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Elected Member The American Society for Clinical Investigation, 2008

Clinical Trials

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. Start of enrollment: 2004 Oct 01
Completed
Phase 2
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer Start of enrollment: 2005 Aug 15
Completed
Phase 2
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients Start of enrollment: 2003 Feb 01
Completed
Phase 2
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma Start of enrollment: 2004 Feb 01
Completed
Phase 2
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung Start of enrollment: 2004 Nov 01
Completed
Phase 2
Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 2
Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2005 Nov 01
Completed
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. Start of enrollment: 2012 Dec 18
Completed
Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Start of enrollment: 2014 Sep 26
Recruiting
Not Applicable
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Start of enrollment: 2018 Jan 31
Active, not recruiting
Phase 2
Osimertinib In EGFR Mutant Lung Cancer Start of enrollment: 2018 Aug 13
Recruiting
Phase 2
Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) Start of enrollment: 2019 Jul 09
Recruiting
Phase 1, Phase 2
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Start of enrollment: 2020 Jan 10
Active, not recruiting
Phase 3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada, Jessica K Lee, Joao V Alessi, Adriana Barrichello, Victor R Vaz, Giuseppe Lamberti, Alessandro Di ...> ;Cancer Discovery. 2024 Apr 3
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study.
Leou Ismael Banla, Alice Tzeng, John P Baillieul, Melin J Kandekhar, Kelly J Fitzgerald, Jaclyn LoPiccolo, Holly A Poitras, Daniel E Soto, Julia K Rotow, Lisa Singer, ...> ;JTO Clinical and Research Reports. 2023 Oct 1
6 citations
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Lars D Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Laura Vegar, David Trinh, Allan Hebbert, Christopher R Smith, Svitlana Kulyk, J David Lawson, ...> ;Cancer Discovery. 2023 Nov 1
2 citations
Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.
Francesca Nardi, Naiara Perurena, Amy E Schade, Ze-Hua Li, Kenneth Ngo, Elena V Ivanova, Aisha Saldanha, Chendi Li, Prafulla C Gokhale, Aaron N Hata, David A Barbie, C...> ;The Journal of Clinical Investigation. 2023 Aug 15
2 citations
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.
Cloud P Paweletz, Grace A Heavey, Yanan Kuang, Emily Durlacher, Thian Kheoh, Richard C Chao, Alexander I Spira, Konstantinos Leventakos, Melissa L Johnson, Sai-Hong Ig...> ;Clinical Cancer Research. 2023 Aug 15
29 citations
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Ryan J Hartmaier, Aleksandra A Markovets, Myung Ju Ahn, Lecia V Sequist, Ji-Youn Han, Byoung Chul Cho, Helena A Yu, Sang-We Kim, James Chih-Hsin Yang, Jong-Seok Lee, W...> ;Cancer Discovery. 2023 Jan 9
7 citations
MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer.
Ryohei Yoshida, Maria Saigi, Tetsuo Tani, Benjamin F Springer, Hirofumi Shibata, Shunsuke Kitajima, Navin R Mahadevan, Marco Campisi, William Kim, Yoshihisa Kobayashi,...> ;Cancer Research. 2022 Nov 2
19 citations
Activation of Tumor-Cell STING Primes NK-Cell Therapy.
Erik H Knelson, Elena V Ivanova, Mubin Tarannum, Marco Campisi, Patrick H Lizotte, Matthew A Booker, Ismail Ozgenc, Moataz Noureddine, Brittany Meisenheimer, Minyue Ch...> ;Cancer Immunology Research. 2022 Aug 3
22 citations
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Mengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, Jian Fang, D Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Vi...> ;Cancer Discovery. 2022 Jul 6
7 citations
Combination of type I and type II MET tyrosine kinase inhibitors as therapeutic approach to prevent resistance.
Magda Bahcall, Cloud P. Paweletz, Yanan Kuang, Luke J. Taus, Taebo Sim, Nam Doo Kim, Kshiti Dholakia, Christie J. Lau, Prafulla C. Gokhale, Pratik R Chopade, Fangxin H...> ;Molecular Cancer Therapeutics. 2021 Nov 17
10 citations
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.
Florian Wittlinger, David E. Heppner, Ciric To, Marcel Günther, Bo Hee Shin, Jaimin K. Rana, Anna M Schmoker, Tyler S. Beyett, Lena M. Berger, Benedict-Tilman Berger, ...> ;Journal of Medicinal Chemistry. 2021 Oct 20
1 citations
Tumor growth rate after nadir is associated with survival in patients with egfr-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosin...
Mizuki Nishino, Junwei Lu, Takuya Hino, Natalie I. Vokes, Pasi A. Jänne, Hiroto Hatabu, Bruce E. Johnson> ;JCO Precision Oncology. 2021 Oct 14
132 citations
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 O...
Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Maria Rosario Garcia Campelo, Enrique...> ;JAMA Oncology. 2021 Oct 14
30 citations
A structural model of a Ras-Raf signalosome.
Venkatesh Mysore, Zhi Wei Zhou, Chiara Ambrogio, Lianbo Li, Jonas N. Kapp, Chunya Lu, Qi Wang, Maxwell R. Tucker, Jeffrey J. Okoro, Gabriela Nagy-Davidescu, Xiao Chen ...> ;Nature Structural & Molecular Biology. 2021 Oct 1
18 citations
Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study.
Jean-Louis Pujol, Johan Vansteenkiste, Luis Paz-Ares Rodríguez, Vanesa Gregorc, Julien Mazieres, Mark M. Awad, Pasi A. Jänne, Michael Chisamore, Anwar Hossain, Yanyun ...> ;JTO Clinical and Research Reports. 2021 Sep 25
21 citations
EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody drug conjugate HER3-DXd.
Heidi M. Haikala, Timothy Lopez, Jens Köhler, Pinar O. Eser, Man Xu, Qing Zeng, Tyler Teceno, Kenneth H. Ngo, Yutong Zhao, Elena Ivanova, Arrien A. Bertram, Brittaney ...> ;Cancer Research. 2021 Sep 21
78 citations
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.
Pasi A. Jänne, Christina S. Baik, Wu Chou Su, Melissa Lynne Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steue...> ;Cancer Discovery. 2021 Sep 21
276 citations
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazieres, Misako Nagasaka, Lyudmila Bazhenova, Andreas Saltos, Enriqueta Felip, Jose...> ;The New England Journal of Medicine. 2021 Sep 18
32 citations
Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-i...
David Planchard, P.-H. Feng, N. Karaseva, Sang We Kim, Tae Min Kim, Chee Khoon Lee, A. Poltoratskiy, N. Yanagitani, R. Marshall, X. Huang, P. Howarth, Pasi A. Jänne, K...> ;ESMO Open. 2021 Sep 17
Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors.
Mizuki Nishino, Junwei Lu, Takuya Hino, Natalie I. Vokes, Pasi A. Jänne, Hiroto Hatabu, Bruce E. Johnson> ;Journal of Thoracic Imaging. 2021 Sep 15
11 citations
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer
Pınar Özden Eser, Raymond M. Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Heidi M. Haikala, Ciric To, Jeffrey J. Okoro, Kshiti Dholakia, Jihyun Choi, Yoonji Eum, At...> ;Science Translational Medicine. 2021 Sep 1
6 citations
Amivantamab: Treating EGFR Exon 20-Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation.
Jens Köhler, Pasi A. Jänne> ;Journal of Clinical Oncology. 2021 Aug 2
204 citations
Acquired Resistance to KRASG12C Inhibition in Cancer
Mark M. Awad, Shengwu Liu, Igor I. Rybkin, Kathryn C. Arbour, Julien Dilly, Viola W. Zhu, Melissa Lynne Johnson, Rebecca S. Heist, Tejas Patil, Gregory J. Riely, Josep...> ;The New England Journal of Medicine. 2021 Jun 23
378 citations
Kinase drug discovery 20 years after imatinib: progress and future directions.
Philip Cohen, Darren Cross, Pasi A. Jänne> ;Nature Reviews. Drug Discovery. 2021 May 17
30 citations
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.
James M. Cleary, Srivatsan Raghavan, Qibiao Wu, Yvonne Y. Li, Liam F. Spurr, Hersh Gupta, Douglas A. Rubinson, Isobel J Fetter, Jason L. Hornick, Jonathan A. Nowak, Gi...> ;Cancer Discovery. 2021 Apr 29
Join now to see all

Journal Articles

Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors
Jeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature

Lectures

Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.
2019 ASCO Annual Meeting - 6/1/2019
Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
2019 ASCO Annual Meeting - 6/1/2019
Phase 1 study of the anti-HER3 antibody drug conjugate U3-1402 in metastatic or unresectable EGFR-mutant NSCLC.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven CancersJune 2nd, 2022
Takeda Pharmaceutical : EXKIVITY (Mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLCSeptember 20th, 2021
WCLC 2021: KRAS Drugs May Do Best in Tough SubtypeFebruary 2nd, 2021
Join now to see all

Grant Support

The Use Of Whole-Exome Sequencing To Guide The Care Of Cancer PatientsNational Human Genome Research Institute2012
EML4-ALK: A Potential Therapeutic Target In Lung CancerNational Cancer Institute2009–2012
Drug Resistance In Lung CancerNational Cancer Institute2008–2011
Mechanisms Of Acquired Resistance To Egfr-Targeted AgentsNational Cancer Institute2008–2009